Emeis

EMEIS.PA

Medical - Care Facilities · Healthcare

Exchange

Euronext Paris

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Mixed

Growth

Good

Cash Flow

Weak

Stability

Weak

Valuation

Data not available

Dividends

Good

Track this stock — start free trial

Winston Score History

The full picture

Emeis (formerly known as Orpea) is a European company that runs nursing homes, assisted-living facilities, and rehabilitation clinics for elderly and dependent people. Its main customers are seniors who need daily care, as well as patients recovering from surgery or illness. The company operates thousands of care facilities across Europe, making it one of the largest private long-term care operators on the continent.

Emeis earns money by charging residents and patients fees for accommodation, meals, and medical care, with a significant portion of revenue coming from government health reimbursements and social insurance programs. It operates primarily in France, Belgium, Germany, and several other European countries, and its scale gives it some purchasing power, though competition from other private operators and public facilities is intense. The company is still recovering from a major 2022 scandal involving neglect allegations at its French facilities, and rebuilding trust with regulators, residents, and investors remains its most pressing challenge.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+107.1% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+48.8% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

37.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

€337M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Emeis grew revenue 107% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

15.6%

Thin — 15.6% gross margin

Profit after running costs

Operating Margin

15.6%

Healthy — 15.6% operating margin

Return on the money invested

ROCE

6.8%

Weak — 6.8% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+72.6%

Fast-growing sales (+72.6% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

7.7%

Modest free cash flow (7.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

2.11

Heavy debt load (2.11)

Covers its interest

Interest Cover

1.29x

Dangerous — barely covers interest (1.3x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

0.55%

no trend

Small dividend — 0.55% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

+40.0%

no trend

Dividend growing fast (40.0% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial